The regulatory agencies need to have pro-active approach in handling clinical trials throughout the globe. FDA as well as other regulatory bodies should continue to encourage unbiased gender and race participation in the clinical trials. Prospective design of clinical trials for sex analysis would provide more relevant statistical information. Trust, communication, education, and building a presence within the community are successful means to increasing diversity in clinical trials. Collaborative efforts are essential across all sectors of medical product research and development. Regulatory and review bodies must focus on patientsâ needs and facilitate the clinical trial process. Saba Nabi, Clinical trials: Australian prospective view.
Last date updated on June, 2014